The first localized bioreactor project of upstream total DCS control system

2020

First 10000L scale upstream and downstream process turnkey project for antibody production in China (PCS7+Batch)

2020

The first localized bioreactor project of upstream total DCS control system


  • Seed bioreactor

  • Main production bioreactor

  • Media preparation system

  • Media feeding system

  • Centrifuge control and integration

  • Harvest skid

  • Deep filtration system

  • Upstream CIP systems

2020

First 10000L scale upstream and downstream process turnkey project for antibody production in China (PCS7+Batch)


  • Medium Prep.

  • Medium Storage

  • Boundary Integration with Bio-reaction Train

  • Buffer Prep.

  • Buffer Storage

  • Harvest and filtration

  • Purification skids

  • Purification integration (Chroma, inline preparation)

  • CIP/SIP

2020

Antibody turnkey project

2020

22000Lx4 Antibody bioreactor project

2021

Antibody turnkey project


  • Drug substance workshop process concept design

  • ZETA Bioreactor 30-20000L

  • Media preparation and storage & distribution system

  • Buffer preparation and storage & distribution system

  • Intermediate products and purification equipment integration

  • CIP/SIP system

  • Lifecycle project management

  • Process automation system, including third-party equipment integration and data management

  • Support for commissioning and trial production

  • DQ、IQ、OQ

  • Preventive maintenance

2020

22000Lx4 Antibody bioreactor project


  • Super Skid

  • Dynamic test before delivery

  • Fast delivery and commissioning

  • Customized for commercial production

2021

200L Pilot Bioreactor Project

2023

CHO Perfusion Cultivation

2024

200L Pilot Bioreactor Project


  • Biomanufacturing

  • Pichia Pastoris

  • Collagen

2023

CHO Perfusion Cultivation


  • High-density cell culture, with cell density 5–10 times higher than batch processes, achieving target protein titers of 5–20 g/L.

  • Continuous production, where target proteins are continuously secreted and harvested, with single-batch operation cycles lasting up to 30–60 days.

  • High-quality product output, enabled by stable culture conditions that reduce apoptosis and impurities, resulting in more homogeneous glycosylation modification of the product.

  • Cost-effectiveness optimization, as continuous harvesting minimizes product degradation losses.

2024

Bioprocess technology services platform

2025

Bioprocess technology services platform


  • Bioreactor Data Base + Process Cloud

  • Characterization of Bioreactor Process Scale Up

  • Bioprocess PAT Technology

  • Bioprocess Consulting and Solutions

2025